Aimmune Therapeutics, Inc.·4

Oct 15, 7:18 PM ET

Societe des Produits Nestle S.A. 4

4 · Aimmune Therapeutics, Inc. · Filed Oct 15, 2020

Insider Transaction Report

Form 4
Period: 2020-10-13
Transactions
  • Purchase

    Common Stock

    2020-10-13$34.50/sh+43,435,583$1,498,527,61443,435,583 total(indirect: See footnote)
  • Purchase

    Common Stock

    2020-10-13$34.50/sh+10,681,704$368,518,78823,408,817 total(indirect: See footnote)
Holdings
  • Common Stock

    12,727,113
  • Series A Preferred Stock

    525,634
Footnotes (3)
  • [F1]All of the shares were cancelled on October 13, 2020 pursuant to the terms of that certain Agreement and Plan of Merger, dated as of August 29, 2020 (the "Merger Agreement"), by and among Societe des Produits Nestle S.A. ("SPN"), SPN MergerSub, Inc., a wholly owned subsidiary of SPN ("Merger Sub"), and Aimmune Therapeutics, Inc. ("Aimmune"). Following effectiveness of the merger provided for in the Merger Agreement, SPN owns 100 shares of the common stock of Aimmune, which became a wholly owned subsidiary of SPN as a result of such merger, which represents all of the outstanding shares of common stock of Aimmune.
  • [F2]Shares acquired by Merger Sub, upon acceptance of all shares validly tendered and not validly withdrawn pursuant to the tender offer by Merger Sub and SPN, pursuant to the Merger Agreement, for any and all outstanding shares of Aimmune common stock pursuant to that certain Offer to Purchase dated September 14, 2020.
  • [F3]Shares acquired pursuant to the merger provided for in the Merger Agreement.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION